Other languages Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

Market Closed - Australian S.E. Other stock markets 11:40:51 20/05/2024 am IST			5-day change	1st Jan Change
0.047 ^AUD	+9.30%		+11.90%	-24.19%

25/03	Transcript : Prescient Therapeutics Limited - Special Call
23/02	Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	23/02
Prescient Therapeutics Receives AU$2.4 Million R&D Tax Rebate; Shares Down 4%	28/11
Prescient Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/23/25
Prescient Therapeutics Limited Appoints Ellen Feigal to the Board as Non- Executive Director	15/23/15
Prescient Therapeutics Limited Provides an Update on the PTX-100 Phase 1b Expansion Cohort in Relapsed and Refractory T Cell Lymphomas	16/23/16
Prescient Therapeutics Secures US FDA Orphan Drug Designation for Lymphoma Medication; Shares Surge 29%	09/23/09
Prescient Therapeutics Announces FDA Grants Broader Orphan Drug Status to PTX-100 for TCL Indications	09/23/09
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24
Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	24/23/24
Prescient Therapeutics Limited Announces PTX-100 Trial Update	25/22/25
Prescient Therapeutics Unveils Cancer Drug CellPryme-A; Shares Rise 3%	23/22/23
Prescient Therapeutics Unveils CellPryme-A to Boost Car-T Performance	23/22/23
Prescient Therapeutics, MD Anderson Cancer Center to Develop Blood Cancer Binder for OmniCAR; Shares Rise 3%	07/22/07
Prescient Therapeutics Announces a Strategic Collaboration with the Larger Cancer Centre in the US1, the University of Texas MD Anderson Cancer Center	07/22/07
Prescient Therapeutics Launches $6 Million Share Purchase Plan	24/22/24
Prescient Therapeutics Limited Signs Agreement with Thermo Fisher Scientific to Accelerate OmniCAR Platform Development	18/22/18
Prescient Therapeutics Enters Manufacturing Deal for CAR-T Therapy OmniCAR for Clinical Trials Ahead	16/22/16
Prescient Therapeutics Secures Orphan Drug Designation in US for Lymphoma Drug; Shares Rally 19%	15/22/15
Prescient Therapeutics Secures US Patent for OmniCAR Platform; Shares Rise 6%	05/22/05
Prescient Therapeutics Launches New Cell Therapy Manufacturing Enhancement Technology; Shares Fall 7%	08/22/08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Prescient Therapeutics Limited

Equities

PTX

AU000000PTX3

Other languages

Filters